Abstract
Malaria in pregnancy (MiP) poses a dangerous health risk to both mothers and their fetuses, causing severe outcomes such as preterm delivery, intrauterine growth restriction, miscarriage, stillbirth, and neonatal and maternal death. Plasmodium falciparum infected erythrocytes sequester in placental intervillous spaces causing placental malaria (PM), eliciting inflammatory responses associated with severe sequelae. Current MiP prevention strategies have improved pregnancy outcomes, but serious morbidity and mortality persist. Vaccines to prevent MiP and PM are under development and are expected to improve pregnancy outcomes. To prepare for safety and efficacy trials of these vaccines, the incidence of adverse pregnancy outcomes including those caused by MiP should be documented at clinical sites. This review summarizes reported key adverse pregnancy outcomes attributable to MiP, providing important baseline context to define measurable safety and efficacy endpoints for malaria vaccine trials in pregnancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
